Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis

被引：0
|
作者：
Hawkins, P.N. [1 ]
Aprile, C. [2 ,5 ]
Capri, G. [3 ]
Vigano, L. [3 ]
Munzone, E. [3 ]
Gianni, L. [3 ]
Pepys, M.B. [1 ]
Merlini, G. [4 ]
机构：
[1] Immunological Medicine Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom
[2] Nuclear Medicine Service, Scientific Institute Fondazione Maugeri, Pavia, Italy
[3] Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
[4] Biotechnology Research Laboratories, University Hospital S. Matteo, Pavia, Italy
[5] Fond. S.Maugeri- Nuclear Med. Serv., 8,v.Ferrata, I- 27100 Pavia, Italy
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 1998年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
19
引用
收藏
页码：701 / 708
相关论文
共 50 条
  • [31] Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component
    Pepys, Mark B.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 : 5 - 6
  • [32] 1-TRIIODOTHYRONINE MODIFICATION OF SHORTENED HALF-LIFE OF RADIOACTIVE IODINE . STUDIES IN ACCELERATED IODINE-131 TURNOVER IN THYROID TISSUE
    HEINZE, HG
    SONNTAG, A
    FORTSCHRITTE AUF DEM GEBIETE DER RONTGENSTRAHLEN UND DER NUKLEARMEDIZIN, 1968, : 146 - &
  • [33] Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
    M. B. Pepys
    J. Herbert
    W. L. Hutchinson
    G. A. Tennent
    H. J. Lachmann
    J. R. Gallimore
    L. B. Lovat
    T. Bartfai
    A. Alanine
    C. Hertel
    T. Hoffmann
    R. Jakob-Roetne
    R. D. Norcross
    J. A. Kemp
    K. Yamamura
    M. Suzuki
    G. W. Taylor
    S. Murray
    D. Thompson
    A. Purvis
    S. Kolstoe
    S. P. Wood
    P. N. Hawkins
    Nature, 2002, 417 : 254 - 259
  • [34] Fibril protein folding and serum amyloid P component as therapeutic targets in amyloidosis
    Pepys, MB
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 : S105 - S105
  • [35] Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
    Pepys, MB
    Herbert, J
    Hutchinson, WL
    Tennent, GA
    Lachmann, HJ
    Gallimore, JR
    Lovat, LB
    Bartfai, T
    Alanine, A
    Hertel, C
    Hoffmann, T
    Jakob-Roetne, R
    Norcross, RD
    Kemp, JA
    Yamamura, K
    Suzuki, M
    Taylor, GW
    Murray, S
    Thompson, D
    Purvis, A
    Kolstoe, S
    Wood, SP
    Hawkins, PN
    NATURE, 2002, 417 (6886) : 254 - 259
  • [36] ROLE OF SERUM AMYLOID-P COMPONENT FOR SYSTEMIC AMYLOIDOSIS IN TRANSGENIC MICE CARRYING HUMAN MUTANT TRANSTHYRETIN GENE
    TASHIRO, F
    YI, S
    WAKASUGI, S
    MAEDA, S
    SHIMADA, K
    YAMAMURA, K
    GERONTOLOGY, 1991, 37 : 56 - 62
  • [37] The liver in systemic amyloidosis:: insights from 123I serum amyloid P component scintigraphy in 484 patients
    Lovat, LB
    Persey, MR
    Madhoo, S
    Pepys, MB
    Hawkins, PN
    GUT, 1998, 42 (05) : 727 - 734
  • [38] SYSTEMIC OR LOCALIZED AMYLOIDOSIS - USEFULNESS OF SERUM AMYLOID-P COMPONENT SCINTIGRAPHY AND LABIAL SALIVARY-GLAND BIOPSY
    HACHULLA, E
    WECHSLER, B
    DEVEAUX, M
    GODEAU, P
    HATRON, PY
    DEVULDER, B
    JANIN, A
    MARCHANDISE, X
    REVUE DE MEDECINE INTERNE, 1994, 15 (03): : 182 - 185
  • [39] Normal circulating serum amyloid P component concentration in systemic sclerosis
    Tennent, Glenys A.
    Dziadzio, Magdalena
    Triantafillidou, Eva
    Davies, Phillip
    Gallimore, J. Ruth
    Denton, Christopher P.
    Pepys, Mark B.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (06): : 2013 - 2017
  • [40] Serum amyloid P component (SAP) in systemic lupus erythematosus (SLE)
    Voss, A
    Nielsen, EH
    Svehag, S
    Junker, P
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 291 - 291
12345